10 Years of SGLT2 Inhibitors: A Decade of Redefining Cardiometabolic Care
This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
Source: hcplive.com